

Higher seroprotection rates (SPR) and higher anti-HBs concentrations in adults age 18-45 immunized with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal, double-blind, randomized Phase 3 study (CONSTANT)

Francisco Diaz-Mitoma¹, Timo Vesikari², Adam Finn³, Pierre van Damme⁴, Isabel Leroux-Roels⁵, Geert Leroux-Roels⁵, Geert Leroux-Roels⁵, Geert Leroux-Roels⁵, Ronnie Aronson¹⁰, Dennis Reich¹¹, Hamilton Sah¹², Samir Arora¹³, Peter J Ruane¹⁴, Corey Anderson¹⁵, Clancy L. Cone¹⁶, Michael Manns¹⁷, Catherine Cosgrove¹⁸, Saul N. Faust¹⁹, Maheshi N. Ramasamy²⁰, Nathalie Machluf¹, Johanna N. Spaans¹, Bebi Yassin-Rajkumar¹, David Anderson¹, Vlad Popovic¹, for the CONSTANT Study Group

Lower Saxony, Germany; ¹⁸St. George's University Hospital NHS Foundation Trust, Southampton, UK; ²⁰Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital and University of Oxford, Oxford, UK

INTRODUCTION

- Hepatitis B Virus (HBV) remains a significant public health risk, with an estimated 240-350 million people chronically infected worldwide
- In Canada, an estimated 250,000-460,000 individuals have chronic hepatitis B, with highest rates found in urban centres¹
- Though infection rates in Canada have declined, reported acute infection rates are likely an underestimate because of the asymptomatic nature of the disease, and therefore patients do not get tested and remain unidentified²
- Rates of new HBV infections are highest among individuals age 30-39 years, underscoring the importance of continued adult vaccination against HBV, as well as the need for a highly effective and safe HBV vaccine with a rapid onset of protection
- 3A-HBV is a 3-antigen HBV vaccine that contains all three HBV surface antigens (HBsAg) – S, pre-S1, and pre-S2 – is adjuvanted with alum, and manufactured in mammalian CHO cells
- The pre-S1 antigen induces key neutralizing antibodies that block virus-receptor binding. T cell response to pre-S1 and pre-S2 antigens could further boost responses to the S antigens, resulting in a more immunogenic vaccine^{3,4}

STUDY OBJECTIVES & DESIGN

[NCT03408730]

- The CONSTANT study was one of two studies in the pivotal Phase 3 program of 3A-HBV that was conducted from 2017-2020
- CONSTANT was a four-arm lot-to-lot consistency study
- **Primary Objective :** To demonstrate the manufacturing equivalence, in terms of immunogenicity, of 3 independent consecutive lots of 3A-HBV at Day 196, four weeks post-3rd vaccination
- Secondary and Exploratory Objectives :
- Safet local phys even of ch
- Immı titers

fety, tolerability, and reactogenicity : Standardized methods for al and systemic vaccine reactions, repeated vital signs and vsical examinations, 48 weeks follow-up for serious adverse ents (SAEs), medically-significant events (MAAEs) or new onset chronic illness (NOCI), and changes in concomitant medication <i>munogenicity :</i> Seroprotection rates (SPR), GMC of anti-HBs rs, and kinetics of immunogenicity			Pooled 3A-HBV n=2,124 (% of subjects)	1A-HBV <i>n</i> =712 (% of subjects)
		Vaccine withdrawal due to AE/SAE	0.5	0.3
		Study discontinuation due to AE/SAE	0.4	0.1
		Local Reactogenicity (most common)		
		Injection site pain	75.6	53.9
2 8 3 8		Injections site tenderness	75.1	54.9
N size 2,838		Systemic Reactogenicity (most common)		
18-45 years		Myalgia	44.4	32.4
10 µg		Fatigue	40.1	39.9
Control Vaccine 20 µg 1A-HBV		Headache	38.2	37.6
		Treatment-emergent AEs (TEAEs)	53.1	52.1
		Medically-attended AEs (MAAEs)	21.7	17.6
Random. 1:1:1:1		New Onset of Chronic Illness (NOCI)	1.6	1.1
0, 4, 24 weeks		SAEs	2.0	0.4
	_	Death	1	0
	ne reactions, repeated vita 8 weeks follow-up for series ignificant events (MAAEs) of and changes in concomitant otection rates (SPR), GMC unogenicity 2,838 18-45 years 10 µg 20 µg 1A-HBV 1:1:1:1	ne reactions, repeated vital signs and 8 weeks follow-up for serious adverse significant events (MAAEs) or new onset and changes in concomitant medication btection rates (SPR), GMC of anti-HBs unogenicity 2,838 18-45 years 10 µg 20 µg 1A-HBV 1:1:1:1	ne reactions, repeated vital signs and 8 weeks follow-up for serious adverse significant events (MAAEs) or new onset and changes in concomitant medication btection rates (SPR), GMC of anti-HBs inogenicityVaccine withdrawal due to AE/SAE Study discontinuation due to AE/SAE2,838Local Reactogenicity (most common) Injection site pain Injection site tenderness2,838Systemic Reactogenicity (most common)18-45 yearsMyalgia Fatigue Headache20 µg 1A-HBVTreatment-emergent AEs (TEAEs)1:1:1:1New Onset of Chronic Illness (NOCI) SAEs	ne reactions, repeated vital signs and B weeks follow-up for serious adverse significant events (MAAEs) or new onset and changes in concomitant medication otection rates (SPR), GMC of anti-HBs inogenicityVaccine withdrawal due to AE/SAE0.52,8385tudy discontinuation due to AE/SAE0.40.418-45 years10 µg75.61njection site pain75.610 µgMyalgia44.444.420 µg 1A-HBVTreatment-emergent AEs (TEAEs)53.11:1:1:1Medically-attended AEs (MAAEs)21.70, 4, 24 weeksSAEs2.0

Ind - Sc

Par

- Fe

Rac

- O Eth

- No

Cοι

Wit


Cor

STUDY SUBJECT DISPOSITION

dividuals Screened	4,452				
Screened Failure	1,614 (36%)				
rticipants Randomized	2,838 at 35 study sites				
nical Study Arms	Lot A 3A-HBV	Lot B 3A-HBV	Lot C 3A-HBV	1A-HBV	
rticipants Randomized	711	709	706	712	
ean Age	33.8	32.9	33.9	33.4	
ender					
/lale	303 (43%)	313 (44%)	291 (41%)	291 (41%)	
emale	408 (57%)	396 (56%)	415 (59%)	421 (59%)	
an BMI	25.9	25.8	26.0	25.7	
ce					
Vhite	650 (91%)	642 (91%)	651 (92%)	654 (92%)	
sian	9 (1%)	15 (2%)	13 (2%)	9 (1%)	
Black or African American	46 (7%)	43 (6%)	34 (5%)	38 (5%)	
Other	6 (1%)	9 (1%)	8 (1%)	11 (2%)	
hnicity					
lispanic or LatinX	64 (9%)	70 (10%)	61 (9%)	74 (10%)	
Ion-Hispanic or LatinX	643 (90%)	639 (90%)	644 (91%)	636 (89%)	
lot collected	4 (1%)	0 (0%)	1 (0.1%)	2 (0.3%)	
ountry/Region					
Jnited States	191 (27%)	187 (26%)	186 (26%)	188 (26%)	
Europe	489 (69%)	493 (70%)	490 (70%)	493 (69%)	
Canada	31 (4%)	29 (4%)	30 (4%)	31 (4%)	
thdrew	75 (10.5%)	72 (10.2%)	81 (11.5%)	69 (9.7%)	
mpleted Study	636 (89.5%)	637 (89.8%)	625 (88.5%)	643 (90.3%	

SAFETY & TOLERABILITY RESULTS

IMMUNOGENICITY RESULTS



3A-HBV N = 1,753(pooled data)

N = 592

1A-HBV

DISCLOSURE

Dr. Francisco Diaz-Mitoma is the Chief Medical Officer of VBI Vaccines Inc.

REFERENCES

- I. Sherman, M. 2013. Canadian Liver Foundation
- 2. Coffin CS et al. 2018. Canadian Liver Journal
- 3. Heermann KH et al., J Virol. 1984;52(2):396-402
- 4. Milich DR et al. Science. 1985;228(4704):1195-1199.



- and with no increase of reactogenicity with subsequent dosing
- SAEs uncommon with either vaccines

We thank all clinicians, nurses, and volunteers who contributed to this study. The contribution of scientists and technologists at VBI Vaccines Inc. is greatly appreciated.

CONTACT INFORMATION

Dr. Francisco Diaz-Mitoma fdiazmitoma@vbivaccines.com

